"PML" Archive - MS-Docblog

Bei Multipler Sklerose helfen Medikamente. Die können aber auch Nebenwirkungen haben.

Side Effects of MS Therapies: Natalizumab

23. February 2023 Prof. Dr. med. Mathias Mäurer General, MS Therapy

Natalizumab (Tysabri®) inhibits the migration (transmigration) of inflammatory cells into the central nervous system and was the first monoclonal antibody approved for the treatment of relapsing multiple sclerosis.

Efficacy of Natalizumab Proven Even with Extended Dose Interval

4. October 2021 Prof. Dr. med. Mathias Mäurer General, MS Therapy

There is news about Natalizumab (Tysabri®), which was expected, but it is still good that clarity now exists: In August 2021, the first results of the NOVA study were communicated, which compared the effectiveness of

“Extended Dosing” with Natalizumab – A Sensible Strategy for Reducing the Risk of PML?

9. August 2018 Prof. Dr. med. Mathias Mäurer Therapy for MS

Tysabri® (Natalizumab) is undoubtedly a very effective and well-tolerated drug for the treatment of active Multiple Sclerosis. Many patients have benefited from the treatment in the past and were satisfied with the effects and individual

Natalizumab – what does the JCV antibody index mean?

9. June 2016 Prof. Dr. med. Mathias Mäurer General

Lately, I’ve been receiving more inquiries from Tysabri patients (active ingredient Natalizumab), who are worried about a high JCV antibody index that has been measured in them. Therefore, I would like to briefly explain what

Lymphocytopenia under Tecfidera

27. May 2016 Prof. Dr. med. Mathias Mäurer MS Therapy

Dimethyl fumarate (Tecfidera®) has established itself as a first-line therapy for the treatment of multiple sclerosis. The availability of an effective oral therapy with a favorable side effect profile has expanded the possibilities of MS

Extending the Infusion Intervals of Tysabri – a Sensible Measure in MS?

1. February 2016 Prof. Dr. med. Mathias Mäurer General, Therapy for MS

Tysabri (active ingredient Natalizumab) is given for (highly-) active Multiple Sclerosis every 4 weeks. Recently, it has been frequently mentioned that extending the infusion interval – often the number 8 weeks is mentioned – reduces

Tysabri – what comes after?

25. June 2015 Prof. Dr. med. Mathias Mäurer Therapy for MS

The problem that arises after two years of therapy with Natalizumab (Tysabri®) I had already described in a previous blog post: After two years of therapy, the risk of progressive multifocal leukoencephalopathy (PML) increases for

Tysabri – There is No 2-Year Limit for Therapy

24. April 2015 Prof. Dr. med. Mathias Mäurer MS Therapy

“Tysabri® can only be given for 2 years.” – I hear this sentence quite often, and it is definitely not correct! Natalizumab can ultimately be given lifelong, or – perhaps more realistically formulated – Tysabri®

First PML Case under Tecfidera

6. March 2015 Prof. Dr. med. Mathias Mäurer General

This case is not exactly new – to be precise, the news came out in October 2014 – nevertheless, I keep hearing inquiries about the situation, which is why I would like to briefly comment

What is PML actually?

24. February 2015 Prof. Dr. med. Mathias Mäurer General

As neurologists, we are well familiar with the term “PML”. In fact, I almost have to be grateful that a patient recently asked me quite sincerely what it actually is.

Tag: “PML”

Side Effects of MS Therapies: Natalizumab

Efficacy of Natalizumab Proven Even with Extended Dose Interval

“Extended Dosing” with Natalizumab – A Sensible Strategy for Reducing the Risk of PML?

Natalizumab – what does the JCV antibody index mean?

Lymphocytopenia under Tecfidera

Extending the Infusion Intervals of Tysabri – a Sensible Measure in MS?

Tysabri – what comes after?

Tysabri – There is No 2-Year Limit for Therapy

First PML Case under Tecfidera

What is PML actually?

Thank You!

Recent Posts

Archive

Categories

Links

Follow us

The Expert

The Topics

The Community